Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 2/20 | 0.36 |
| ▸ | PLG | P00747 | 2/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2087756 | 1.00 | GAA (0.38) | GAAGPR119LMNAMAPK1RAB9A | |
| SCHEMBL1286879 | 0.91 | PARP1 (0.39) | GAAGPR119LMNAMAPK1RAB9A | |
| Trifluoroacetic Acid SCHEMBL6955197 | 0.90 | LMNA (0.40) | GAAGPR119LMNAMAPK1RAB9A | |
| SCHEMBL19211629 | 0.90 | GAA (0.44) | GAAGPR119LMNAMAPK1RAB9A | |
| SCHEMBL8864939 | 0.82 | GPR119 (0.38) | GAAGPR119LMNAMAPK1RAB9A | |
| SCHEMBL8865061 | 0.82 | GPR119 (0.38) | GAAGPR119LMNAMAPK1RAB9A | |
| SCHEMBL6402328 | 0.82 | GPR119 (0.38) | GAAGPR119LMNAMAPK1RAB9A | |
| SCHEMBL13316383 | 0.81 | NR1D1 (0.41) | GAAGPR119LMNAMAPK1RAB9A | |
| SCHEMBL8014230 | 0.81 | GPR119 (0.38) | GAAGPR119LMNAMAPK1RAB9A | |
| SCHEMBL8864744 | 0.81 | GPR119 (0.38) | GAAGPR119LMNAMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188100-B2 | Adenosine derivatives as A2A receptor agonists | NOVARTIS AG (CH) | 2012-05-29 | — | — | US | disclosed |
| EP-2066669-B1 | ADENOSINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20090325967-A1 | ADENOSINE DERIVATIVES AS A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
| EP-1432705-A2 | DUAL ACTION ANTIBIOTICS | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003032962-A2 | DUAL ACTION ANTIBIOTICS | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2003-04-24 | — | — | WO | disclosed |
| WO-2003031441-A1 | MULTIPLE ACTION COMPOUNDS | MORPHOCHEN AKTIENGESELLSCHAFT FÜR KOMBINATORISCHE CHEMIE (DE) | 2003-04-17 | — | — | WO | disclosed |
| WO-2003031443-A1 | DUAL ACTIONS ANTIBIOTICS COMPRISING A OXAZOLDINONE AND A QUINOLONE OR NAPHTHYRIDINONE MOIETY | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2003-04-17 | — | — | WO | disclosed |
| EP-0928787-B1 | Process for the preparation of 3-amino-pyrrolidine derivatives | BASILEA PHARMACEUTICA AG (CH) | 2002-06-05 | — | — | EP | disclosed |
| EP-1138672-A1 | Process for the preparation of 3-amino-pyrrolidine derivatives | Basilea Pharmaceutica AG (CH) | 2001-10-04 | — | — | EP | disclosed |
| JP-2000053642-A | PRODUCTION OF 3-AMINOPYRROLIDINE DERIVATIVE | F HOFFMANN LA ROCHE AG | 2000-02-22 | — | — | JP | disclosed |
| US-5977381-A | Process for making 3-amino-pyrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0928787-A1 | Process for the preparation of 3-amino-pyrrolidine derivatives | F. Hoffmann-La Roche AG (CH) | 1999-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325967-A1 | ADENOSINE DERIVATIVES AS A2A RECEPTOR AGONISTS | ADORA2A, ADORA2B, ADORA1 | GAA 3897/4885GPR119 163/4885LMNA 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.